Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS) gan Bafadhel, M, Sing, D, Jenkins, C, Peterson, S, Bengtsson, T, Fageras, M

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials gan Bafadhel, M, Peterson, S, Blas, D, Calverley, P, Rennard, S, Richter, K, Fagerås, M

Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD gan Bafadhel, M, Singh, D, Jenkins, C, Peterson, S, Bengtsson, T, Wessman, P, Fageras, M

Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis gan Bafadhel, M, Peterson, S, De Blas, M, Calverley, P, Rennard, S, Richter, K, Fageras, M